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Hereditary Equine Regional Derma Asthenia (HERDA) is a painful disfiguring
autosomal recessive skin disorder of Quarter Horse lineages. Affected horses cannot be
ridden and most are humanely destroyed. Five years following homozygosity mapping of
a putative causal mutation responsible for HERDA, it remains unclear how this mutation
causes the HERDA syndrome. HERDA horses have a missense mutation in peptidylprolyl cis-trans isomerase B (PPIB) which encodes cyclophilin B (CYPB) and alters
folding and post-translational modifications of fibrillar collagen. Loss of function
mutations in CYPB recognized in other species classically present as the debilitating
bone disease, severe to lethal osteogenesis imperfect (OI). Objectives of this study were
to develop a novel method for cryogenic clamping of tendons and ligaments of high
tensile strength and validate its performance by ultimate tensile strength testing of normal
equine deep digital flexor tendon. This validated method was then used to compare
tendon and ligament of HERDA vs. control horses along with great vessels and skin. We
hypothesized that all tissues of high fibrillar collagen content would have altered tensile
properties due to the CYPB mutation affecting fibrous connective tissue globally within

HERDA horses. Based on previous studies in our laboratory identifying reduced
hydroxylysine content and altered collagen crosslink ratios in the skin of HERDA
affected animals that implicate lysyl hydroxylase-1 (LH1) dysfunction, we hypothesized
that the HERDA PPIB mutation modified an interaction between CYPB and LH1,
interfering with hydroxylysine synthesis and its availability for collagen crosslink
formation. In addition, we hypothesized that mutant CYPB may also lead to
modifications of other known CYPB protein complexes, such as the CYPB, prolyl-3
hydroxylase-1 (P3H1) and cartilage associated protein (CRTAP) triplex. Goals of this
study were to investigate the tensile properties of tissues with high fibrillar collagen
content from HERDA homozygotes, to elucidate the mechanistic relationship of the
HERDA CYPB mutation to the clinical disease, and to provide evidence to substantiate a
heterozygote phenotype in HERDA which could be useful to explaining the correlation
between lineages that carry the HERDA allele and performance outcomes in the
discipline of western cutting competition.
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CHAPTER I
INTRODUCTION

Disease Overview
Hereditary equine regional dermal asthenia (HERDA), originally termed
hyperelastosis cutis (HC), was first clinically described by Learner and McCrackin in
1978 (Lerner, 1978). It has since been described in Quarter Horses and related breeds on
three continents (Lerner, 1978; Borges, 2005; Rendle, 2008). The disease is characterized
by fragile skin that is velvety in texture, loose and hyper-extensible which tears easily
and exhibits impaired healing (Lerner, 1978; Hardy, 1988; Pascoe, 1999; Stannard, 2000;
White, 2004, 2007). Skin is easily stretched and manipulated, especially along the
dorsum of the horse, and predisposes the animal to formation of hematomas, seromas and
often severe lacerations from only minor trauma. Clinical signs are often inapparent at
birth (Lerner, 1978; Hardy, 1988; Brounts, 2001; White, 2004, 2007) but develop within
the first two years of life, often noticed at the time of first saddling (Lerner, 1978; Hardy,
1988; Stannard, 2000). While there is some variation in disease severity (White, 2004;
Grady, 2009; Ishikawa, 2012), skin lesions tend to progressively worsen in incidence and
severity with age (White, 2004), making HERDA horses unsuitable for riding as well as
breeding (Lerner, 1978; Hardy, 1988; Brounts, 2001; White, 2004, 2007). Accordingly,
most HERDA horses are humanely euthanized.
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Originally suspected to be of autosomal recessive inheritance, extensive pedigree
analysis (Hardy, 1988; White, 2004; Rashmir-Raven, 2004) of HERDA affected
individuals confirmed (Tryon, 2005) this, along with discovery of consanguinity to a
prominent Quarter Horse stallion, Poco Bueno and/or his dam or sire (King and Miss
Taylor) (Rashmir-Raven, 2004).
After initial recognition of HERDA as a disease entity in horses, attempts were
made to describe histological changes associated with affected animals for diagnostic
purposes (Lerner, 1978; Gunson, 1984; Solomons, 1984; Hardy, 1988; Brounts, 2001;
Borges, 2005; White, 2004, 2007). Although controversial and subject to pathologic
interpretation (Brounts, 2001; Rashmir-Raven, 2004; Borges, 2005), recognition of
‘Zonal Dermal Separation’ became the initial HERDA diagnostic modality. The
discovery of an increased ratio of collagen crosslink degradation products within the
urine of HERDA affected horses by Swiderski et al. (Swiderski, 2007) then made noninvasive diagnosis possible at birth, prior to onset of clinical signs of disease. In 2007,
homozygosity mapping identified a c.115G>A missense mutation in the gene encoding
Cyclophilin B (PPIB) in 64 HERDA affected horses, segregating with inbreeding loops
in the genealogy of affected horses (Tryon 2007). This was proposed to be the putative
causal mutation for HERDA and heterozygosity for this mutation has now become the
standard for identification of both clinically affected and inapparent HERDA carriers
(Lee, 2008; Tryon, 2009; Ishikawa, 2012).
The mechanism by which the PPIB mutation leads to the classic skin phenotype
seen in HERDA affected horses is still unclear. Cyclophilin B (CYPB) is a member of the
peptidyl-proplyl isomerase family of proteins which execute several chaperoning
2

functions (Steinmann, 1991; Lodish, 1991; Endrich, 1999; Kozlov, 2010) within the
endoplasmic reticulum (ER) and Golgi (Zhang, 2003) of cells, including facilitation of
the proper folding of collagen proteins (Bachinger, 1987; Liu, 1990; Smith, 1995; Horibe,
2002; Canty, 2005; Ishikawa, 2009). Mutations in CYPB that destroy CYPB function are
recognized in other species and classically present as the debilitating bone disease severe
to lethal Osteogenesis Imperfecta (Marini, 2007; Choi, 2009; Barnes, 2010; van Dik,
2009; Pyott, 2011), a disorder characterized by osteoporosis, bone fragility, bone
deformity, tooth malformations, short stature, and shortened life span (King, 1971). By
contrast, to date a clinically evident bone phenotype has not been identified in horses
homozygous for the HERDA allele.
The distinctive HERDA phenotype most closely resembles a subtype of a group
of the heterogenous inherited connective tissue disorders termed Ehlers-Danlos syndrome
(EDS) (Lerner, 1978; Hardy, 1988; Brounts, 2001; White, 2004). This subtype, EDS
VIA, is characterized by skin hyperextensibility, articular hypermobility, and tissue
fragility (Beighton, 1998; Mao, 2001; Fernandes, 2008). EDS VIA is an autosomal
recessive disease caused by mutations in the gene procollagen-lysine, 2-oxoglutarate 5dioxygenase-1 (PLOD1) which lead to reduced to absent biological activity of the
enzyme lysyl hydroxylase-1 (LH1), which PLOD1 encodes (Pousi, 1998; Yeowell, 2000;
Walker, 2004). LH1 is responsible for hydroxylation of lysine residues in procollagen
peptides (Myllylä, 1988). EDS VIA individuals have significantly decreased procollagen
hydroxylysine residues, essential for formation of covalent pyridinium crosslinks, in their
collagen (Pasquali, 1997; Mao, 2001; Fernandes, 2008). Furthermore, the ratio between
the 2 most common pyridinium crosslinks, deoxypyridinoline (DPD): pyridinoline (PYD)
3

is greatly increased, which is currently the standard diagnostic screening test for this
condition in man (Pasquali, 1994, 1997; Mao, 2001; Fernandes, 2008). Interestingly, we
have documented that HERDA affected horses also exhibit reduced total hydroxylysine
residues in skin and an increased ratio of DPD: PYD in both skin and urine, (Swiderski,
2006; Hill, 2010) while LH1 activity is normal (Pasquali, unpublished).
Recently, it was found that the HERDA mutated CYPB retains cis-trans
isomerization activity, but shows delayed collagen folding and secretion (Ishikawa, 2012)
without the increase in lysine hydroxylation, termed over modification, that is typically
associated with delay in secretion (Willing, 1988; Cabral, 2007; Christiansen, 2010). The
region on the CYPB protein altered by the HERDA mutation appears to be unassociated
with cis-trans isomerization catalysis, but with identification of improperly folded
proteins in the endoplasmic reticulum (Kozlov, 2010) and LH1 association (Ishikawa,
2012).
While Tryon et al. (2005), through Bayesian statistical methods and meticulous
breeding records, estimated the allelic frequency of HERDA to be 1.84% in the Quarter
Horse population, the advent of a commercially available genetic test for the HERDA
allele has altered this estimate. Subsequently, more recent estimates of the carrier
frequency of the disorder within the general United States Quarter Horse breed have been
reported at 3.5, 4.2 and 9.2% (Tryon, 2007, 2009; Ishikawa, 2012). Remarkably, in a
subset of the Quarter Horse breed, purpose-bred for competition in the western sport of
Cutting, this carrier frequency is reported to be 28.3% (Tryon, 2009), as much as nine
times higher than the general population. Furthermore, a correlation exists between

4

cutting lineages that carry the HERDA allele and performance outcomes in this discipline
(Tipton, 2008; Equistat.com).
Study Objectives
Goals of this study were to investigate global changes in the tensile properties of
HERDA tissues, to elucidate the mechanistic relationship of the mutation to the disease,
and to provide evidence to substantiate a heterozygote phenotype in HERDA, explaining
the correlation between lineages that carry the HERDA allele and performance outcomes
in the discipline of western cutting competition (Tipton, 2008; equistat.com).
The first objective of this study was to determine if the decreased tensile
properties previously demonstrated in skin of HERDA horses (Grady, 2009) can be
identified in other body tissues of similarly high Type I structural collagen content.
We hypothesized that all tissues of high fibrillar collagen content would have
altered tensile properties due to the CYPB mutation affecting fibroblasts globally within
HERDA horses. Testing of this hypothesis was through measurement and comparison of
tensile strength, elastic modulus, and energy to failure of skin, and great vessels; in
addition to comparison of tensile strength of deep and superficial digital flexor tendons
and suspensory ligaments of HERDA affected horses compared to unaffected agematched controls. Facilitation of this study was through first the development of a novel
method for cryogenic clamping of tendons and ligaments of high tensile strength and
validation of clamp performance by ultimate tensile strength testing of normal equine
deep digital flexor tendons.
Building upon prior investigations in our laboratory that identified reduced
hydroxylysine content and altered collagen crosslink ratios in the skin and urine of
5

HERDA affected animals (Swiderski, 2006; Hill, 2010) that are comparable to Lysyl
Hydroxylase-1 (LH1) dysfunction, we further hypothesized that the HERDA PPIB
mutation modifies an interaction between CYPB and LH1, interfering with hydroxylysine
synthesis and its availability for collagen crosslink formation. We also hypothesize that
mutant CYPB would show modified binding affinity within other known CYPB protein
complexes, such as the CYPB, prolyl-3 hydroxylase-1 (P3H1) and cartilage associated
protein (CRTAP) triplex.
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CHAPTER II
A CRYOGENIC CLAMPING TECHNIQUE THAT FACILITATES ULTIMATE
TENSILE STRENGTH DETERMINATIONS IN TENDONS AND LIGAMENTS

Summary
Objective
To describe the use of a cryogenic clamp of novel design for tensile strength
testing of tendinous and ligamentous tissues with inherently high tensile strength. As
published in Veterinary Comparative Orthopaedics and Traumatology. 2011;24(5):370-3.
Methods
Inexpensive, easily machined steel clamps were manufactured to facilitate rapid
insertion into a standard wedge-screw grip apparatus installed on a Bionix 858 Test
Systema with 2350 L Series Controllerb. The deep digital flexor tendon (DDFT) of 6
horses was trimmed to a uniform dumbbell shape and secured in clamps using partial
submersion in liquid nitrogen for approximately 45 seconds and immediately tested.
Approximate time between removal from liquid nitrogen and failure of tendon was 4
minutes.
Results of Study
Failure was achieved in all tendons tested in a region approximating a midpoint
between the clamps. Ultimate failure loads of up to 6745 N were achieved without
slippage of the tissue from the grips. The ultimate tensile strength of the normal equine
DDFT determined in this study was 111.82 +/-11.53 N/mm2, and the stress versus gripto-grip elongation plots for our equine DDFT were representative of a standard non-linear
elastic curve obtained in similar studies.
7

Conclusion and Significance
We present a low cost device for quantifying physical properties of specimens
with high connective tissue concentrations and inherent high tensile strength. Results of
this study indicate that this device provides a practical alternative to other more costly
methods of adequately securing larger tendons and ligaments for tensile strength testing.
Introduction
Tensile testing of connective tissues is logistically difficult because low friction at
the grip-tissue interface often leads to slippage from the grip before the tendon or
ligament ruptures (Rincón, 2001; Riemersma, 1982). Thus, when evaluating tendons and
ligaments, the technique by which the tissue is fixed to a uniaxial tension-compression
machine is of utmost importance. Clamping techniques that have been employed for high
tensile strength tissues include pure mechanical clamps, cryogenic techniques, and
combination of mechanical and cryogenic techniques. These techniques, along with their
advantages and disadvantages, have been previously summarized (Rincón, 2001;
Riemersma, 1982). Systems that utilize the bony attachments of the tendon or ligament as
a means of securing one end of the tissue have a primary limitation because they often
prevent evaluation of multiple specimens from the same limb. Most testing of high tensile
strength connective tissues utilize cryogenic clamping techniques (Riemersma, 1982;
Crevier, 1996; Jansen, 1994; Trudel, 2009). The expense of commercial cryogenic
clamps precludes their use by many investigators, and some previously described custom
cryogenic grips required liquid CO2 (Riemersma, 1982; Crevier, 1996; Jansen, 1994;
Jopp, 2009). In addition, the system we present operates according to the same basic
principal as the cyrofixation assembly employed by Trudel et al. to test rabbit Achilles
8

tendons (Trudel, 2009). However, their system was relatively sophisticated and
incorporated double-wall containers into which liquid nitrogen was fed to secure the
tendons in a block of frozen saline. In addition, a heater was required to prevent freezing
of the tested portion. Therefore, a cryogenic clamp that is inexpensive, simply
manufactured, employs a straightforward technique for adequately chilling and fixing
tissues to the clamp would be beneficial. We present a novel method for cryogenic
clamping of tendons and ligaments of high tensile strength, and validate its performance
by presenting data generated during ultimate tensile strength testing of normal equine
deep digital flexor tendon. In our laboratory this simple cryogenic clamping method has
been used to evaluate differences in the tensile properties of equine tendon and ligament
associated with genetic collagen disorders.
Materials and Methods
A photograph of the device used for quantifying strength is shown in Figure 1.
Integral to the success of the device are wedge-shaped pads (Figure 2) machined from
stainless steel measuring 50.80 mm × 44.45 mm (2.00 in. × 1.75 in.) which clamp
together using four 6.4 mm diameter (0.25 inch diameter and 20 threads per inch) socket
head machine screws. The opposing surfaces of the clamps were machined in a repeating
sinusoidal pattern with a periodicity 12.70 mm (0.50 in.) and peak-to-peak amplitude of
4.44 mm (0.18 in.) to prevent the frozen tissue from slipping. The clamps were
manufactured to facilitate rapid insertion into a standard wedge-screw grip apparatus
installed on a Bionix 858 Test Systema with 2350 L Series Controllerb. The cost to have
the grips fabricated by CNC machining was approximately 1,500 USD.
9

To confirm utility and accuracy of the system, we used the cryogenic grips to
determine the ultimate tensile strength of the equine deep digital flexor tendon (DDFT).
DDFT were harvested from the forelimbs of 6 Quarter Horses ranging in age from 2-7
years (mean of 4.8 years) which were euthanized for non-orthopedic related conditions.
These horses consisted of 4 mares and 2 geldings weighing between 350 and 500 kg.
Animals were managed in accordance with a protocol approved by the University
Institutional Animal Care and Use Committee. Tendons harvested within 4 hours of death
were maintained at -80o C until subjected to mechanical testing. Prior to testing, tendons
were thawed at room temperature in a phosphate buffered saline bath. Using a custom
template and scalpel each tendon was cut into dumbbell shape, as has been described in
other systems (Soslowsky, 2002) so that the ends to be gripped retained their original
width of approximately 18 mm, but the width of the section to be tested was reduced to a
uniform 6 mm. The gauge section spanned that portion of the tendon which had roughly
uniform thickness, and had a minimum length of approximately 30 mm and maximum of
approximately 65 mm. Specimen thickness was determined with a Mach-1™ V500cs
Micromechanical Test Systemc in analogous fashion to a pressure area micrometer. A
plunger lowered onto the tissue at 0.1 mm/sec squeezed the tissue into a rectangular
channel, the dimensions of which were recorded when the applied pressure reached 0.1
MPa. Tissue depth was measured at both ends and at the center of the trimmed, 6-mm
wide section. Specimen depth was taken as the average of the three measurements. The
cross sectional area was calculated as channel width by depth.
Prior to gripping of the tendon, the stainless steel clamps alone were pre-cooled in
liquid nitrogen (-195.8°C) for approximately 45 seconds. The full-width ends of the
10

tendon specimen were then sandwiched between mating jaws of each clamp. Four
machine screws at the corners were used to squeeze the specimen between the jaws.
Screws were tightened just enough to make the specimen conform completely to the
sinusoidal space between opposing grip surfaces so that there were no visible gaps
between tendon and grips (Figure 3). This method preserved as much of the specimen’s
original conformation as possible. The central portion of the specimen, spanning the two
clamps, was loosely wrapped in a latex examination glove to prevent splashing onto the
exposed tissue and the clamps were partially submerged into liquid nitrogen to a depth
approximating 2 cm (Figure 4). Previous investigators have used petroleum jelly to
protect the tested portion of the tendon from dehydration and thermal injury, and it could
be used in our system as well. The duration of liquid nitrogen submersion resulting in
adequate fixation of tissue to the clamps and which did not cause freezing of the tissue
that spanned and suspended the clamps was influenced by specimen cross-sectional area.
Specimen depth ranging from 6.4 to 8.4 mm required 45-70 seconds of submersion. This
timing corresponded to visual observation of partial specimen freezing 1-2mm adjacent
to the clamp, at which time the clamps were removed from liquid nitrogen, mounted in
the materials testing machine, and the specimen was tested immediately.
Tendons were made taught by applying a preload of 10 N and the distance
between clamps (excluding the 1-2mm frozen areas bordering the clamp) defined a
specimen’s gauge length. In our experiments, this length ranged from 29.17 – 62.69mm
(Mean: 45.81). Tendons were distracted at a constant rate of 0.25 mm per second to
failure. Force (N) and displacement (mm) data were recorded at 100 Hz. Data was
plotted as force versus displacement for each tendon. Time from clamp removal from
11

liquid nitrogen to tendon failure approximated 4 minutes in all samples. Stress was
determined by normalizing the force to cross sectional area. Ultimate tensile strength was
defined as the maximum tensile stress.
Results and Discussion
Failure was achieved in all tendons tested at the midpoint between the clamps
(Figure 2) and these results are summarized in Table 1. Ultimate failure loads of up to
6745 N were achieved without complete slippage of the tissue from the grips. Some
stretch of the tissue within the grips immediately adjacent to the gauge section did occur,
but it did not interfere with the ability to achieve failure within the gauge section. This
was attributed to the temperature differential at the edge of the grips which allowed the
tissue to defrost at this site. As tissue within the grips is expected to be rigid, this could
not be accommodated in the mathematical modeling, precluding the calculation of tissue
strain from grip-to-grip displacement data. The ultimate tensile strength of the normal
equine DDFT determined in this study was 111.82 +/-11.53 N/mm2 (N/mm2= MPa), and
the 95% confidence interval was [111.82 N/mm2, 9.23 N/mm2]. In fact, the entire
confidence interval lies between the previously published mean DDFT tensile strengths
of 77 MPa (Crevier, 1996) and 133 MPa (Jansen, 1994). Force versus displacement plots
for our equine DDFT (Figure 5) are representative of a standard non-linear elastic
material curve obtained in similar studies (Crevier, 1996; Jansen, 1994). The method
presented herein does not address measurement of local tissue strain which would be
required to calculate a specimen's elastic modulus.
Three potential complications of this technique include grip failure due to
inadequate freezing of the specimen within the clamps, over-freezing, and limited
12

working time. Though none of the tendons tested in the experimental group experienced
grip failure, we experienced specimen slipping in one instance during development of
this technique. In that case, the clamp was re-applied, re-submerged in liquid nitrogen for
an additional 15 seconds, and the tendon was successfully pulled to failure. This problem
is avoided by precooling the clamps in the liquid nitrogen prior to inserting the specimen,
and determining the optimal time for liquid nitrogen immersion to completely freeze the
specimen within the clamps. Over-freezing of the sample did not occur and is prevented
by optimizing the duration of freezing and close observation. One disadvantage of our
gripping method relative to commercial continuously cooled clamps is shorter working
time due to eventual thawing of the tissue. However, our experiments were consistently
completed within 4 minutes and during this time period thawing of tissue in the clamp
was not problematic. Another potential drawback is the trimming of specimens to a
dumb-bell shape, which would preclude testing tissues with focal lesions. However,
slightly smaller tendons and ligaments could be tested intact. Larger tendons such as the
equine DDFT could possibly be tested intact using larger grips with a longer sine-wave
period. Based on the results of this study, the cryogenic clamping technique presented
herein will be useful for comparing the tensile strength of tendons from horses and other
animals where global differences in the tissue composition would be expected such as
with collagen disorders.
A primary advantage of this gripping system is the use of a sinuous gap between
the grip surfaces which, when combined with freezing, makes this device highly resistant
to slippage. Attempts to test the tissue using conventional flat-faced grips with a grooved
surface always resulted in slippage under tissue compression that was as high as could be
13

achieved manually. Therefore we speculate that freezing the tissue in the wavy pattern
achieved fixation with less tissue compression than would have been required using
conventional, non-freezing grips. This is significant because excess compression pressure
that characterizes many clamping methods leads to increased deformation of the clamped
portions of the specimen. This creates unequal fiber lengths within the specimen itself,
causing uneven load distribution (Riemersma, 1982). We believe the freezing method
described herein may serve to mitigate this effect because the fixation does not rely on
extremely tight squeezing between the grips. Also significant is the wedge-screw
apparatus, which facilitates rapid mounting of the specimen in the servohydraulic testing
machine. This effectively minimizes the time from freezing to initiating a test. Although
preconditioning was not performed in the current study, the tissue remained frozen for
several minutes after mounting which would have been ample time for more
sophisticated loading protocols. Finally, the design of previously described cryogenic
clamps is significantly more complicated, requiring constant circulation of liquid CO2
(Riemersma, 1982; Crevier, 1996; Jansen, 1994) through the clamping device to maintain
freezing. Our clamp method avoids the need for constant cooling, simplifying the
manufacture of this device. Liquid nitrogen is relatively inexpensive and is readily
available at most research-intensive institutions. In our assays, after accounting for
recovery and reuse of residual liquid nitrogen following each assay, 10L was sufficient to
perform at least 25 tests.
In conclusion, this device provides an inexpensive and effective method for
quantifying physical properties of specimens with high connective tissue concentrations
and inherent high tensile strength that lead to specimen slippage during uniaxial
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tension/compression testing. This device incorporates inexpensive, easily machined steel
clamps in which the tissue is held securely by freezing it into a serpentine shape using
liquid nitrogen. Our results substantiate that this device provides a practical alternative to
other more costly methods of securing larger tendons and ligaments for tensile strength
testing.

Table 1

Load and Tensile Strength Determinations for Deep Digital Flexor Tendon
Obtained from Six Normal Horses Using the Described Clamp Apparatus.

Column1

Column2

Horse
1
2
3
4
5
6
Average
Standard
Deviation

Column3

Column4

Thickness
(mm)
6.38
7.96
6.61
7.58
8.41
7.75

CrossSectional Area
(mm^2)
38.27
47.79
39.68
45.47
50.45
46.53

Spec Gauge
Length
(mm)
62.29
35.26
29.17
44.27
52.92
50.92

7.45

44.7

0.79

4.76
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Column5
Load
(N)
4524.7
5226.4
4677.6
5903.2
6744.7
4704.6

Ultimate Tensile
Stress
(MPa)
111.71
103.34
111.38
122.66
126.31
95.54

45.81

5296.9

111.82

12.16

871.7

11.53

Figure 1

Photograph of the Manufactured Clamps Mounted on the Bionix Test
System.

The mounted specimen, an equine deep digital flexor tendon (A), demonstrates failure
(small arrow) that is equidistant from the clamps (B). Clamps are securely mounted in the
wedge-shaped receiver of the test machine (C and D).

16

Figure 2

Schematic Drawing of Wedge-Shaped Clamp Pads Machined from
Stainless Steel.

Height (H) is 50.80 mm × 44.45 mm width (W) (2.00 in. × 1.75 in.). The specimen is
secured within the pads using four 6.4 mm diameter (0.25 inch diameter, 20 threads per
inch) socket head machine screws. The opposing surfaces of the clamps were machined
in a repeating sinusoidal pattern with a periodicity (P) of 12.70 mm (0.50 in.) and peakto-peak amplitude (A) of 4.44 mm (0.18 in.).
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Figure 3

Specimen Mounted in the Wedge-Shaped Clamp Pads.

Sufficient compression is achieved to slightly conform the tendon to the sinusoidal
contour of the clamping surface.
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Figure 4

Clamp Submersion into Liquid Nitrogen.

Clamps are submersed to a depth approximating 2cm by suspending the specimen from a
wire. An exam glove (A) loosely wrapped around exposed tendon (B) to prevent
excessive splashing.
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Figure 5

Representative Stress vs. Elongation curve obtained from Tensile Strength
Testing of Equine Deep Digital Flexor Tendons using Described Method.
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CHAPTER III
TENSILE PROPERTIES IN COLLAGEN RICH TISSUES OF QUARTER HORSES
WITH HEREDITARY EQUINE REGIONAL DERMAL ASTHENIA

Summary
Objective
Hereditary Equine Regional Dermal Asthenia (HERDA) is an autosomal
recessive disorder of Quarter Horses characterized by skin fragility. HERDA horses have
a missense mutation in peptidyl-prolyl cis-trans isomerase B (PPIB) which encodes
Cyclophilin B (CYPB) and alters folding and post-translational modifications of fibrillar
collagen. We hypothesize that tendon, ligament, and great vessels, which like skin are
rich in fibrillar collagen, will also have abnormal biomechanical properties in HERDA
horses.
Methods
Forelimb suspensory ligament, superficial and deep digital flexor tendons;
withers, forelimb, and abdominal skin; main pulmonary artery and the aortic arch were
harvested from six HERDA and six age-matched control horses without the HERDA
allele. Tissues were distracted to failure. Tensile strength (TS) for all tissues, and elastic
modulus (EM) and energy to failure (ETF) for skin and vessels were compared.
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Study Results
HERDA horses had significantly lower TS and EM in tendinoligamentous tissues
and great vessels, respectively. TS, EM and ETF were significantly lower in HERDA
skin. Differences in TS and ETF were more extreme at the withers than the forelimb or
abdomen.
Conclusion and Significance
Tendinoligamentous tissue, great vessels, and skin are significantly weaker in
horses with HERDA than horses lacking the PPIB mutation, substantiating that diverse
tissues with high fibrillar collagen content are abnormal in HERDA and the HERDA
phenotype is not limited to the integument.
Introduction
Hereditary equine regional dermal asthenia (HERDA) is an autosomal recessive
disorder which is characterized by fragile skin that is loose, hyper-extensible and easily
torn (Lerner, 1978; Stannard, 2000; White, 2004, 2007; Tryon, 2005). Horses with
HERDA develop seromas, hematomas, and ulcerations primarily along their dorsum
(Stannard, 2000; White, 2004, 2007). Clinical signs have been reported as early as 2
months of age, but most HERDA affected horses are diagnosed around the time of their
first saddling, at approximately 18 months of age (White, 2004, 2007). While there is
some variation in disease severity, skin lesions tend to progressively worsen in incidence
and severity with age, making HERDA horses unsuitable for riding as well as breeding.
Accordingly, most HERDA horses are humanely euthanized.
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HERDA affects Quarter Horse lineages tracing to the sire Poco Bueno and/or his
dam Miss Taylor (Rashmir-Raven, 2004). Line breeding of these lineages, which are
popular in certain performance disciplines, is credited with concentrating the recessive
HERDA allele within the respective disciplines (Tipton, 2008; Tryon, 2009).
Homozygosity mapping identified a c.115G>A missense mutation in the gene encoding
Cyclophilin B (PPIB) in 64 HERDA affected horses, segregating with inbreeding loops
in the genealogy of affected horses (Tryon, 2007). Heterozygosity for this mutation is
used to identify inapparent HERDA carriers (Lee, 2008; Tryon, 2009). Tryon et al.
(2009) estimated the allelic frequency of HERDA to be 0.142, corresponding to a 28%
carrier rate in the cutting horse subpopulation versus an allelic frequency of .021 (4%
carrier rate) in the Quarter Horse population.
CYPB is a member of the peptidyl-prolyl cis-trans isomerase family of proteins
which catalyze prolyl-containing bonds in procollagen to the trans configuration. This
trans configuration is required to form the triple helical collagen molecule (Bachinger,
1987). Conventionally viewed as the primary rate limiting enzyme in fibrillar collagen
synthesis, CYPB also has critical functions in procollagen trafficking, processing, and
chain association (Canty, 2005; Pyott, 2011). The HERDA mutation does not alter prolyl
isomerization activity of CYPB but delays collagen folding and secretion and modifies a
region of CYPB that identifies improperly folded proteins in the endoplasmic reticulum,
events presumed to alter collagen organization (Tryon, 2007; Ishikawa, 2012; Kozlov,
2010). Despite the global nature of this pathophysiologic mechanism, clinical
manifestation of HERDA is restricted to the integument (White, 2007; Mochal, 2010).
Prior description of significantly reduced tensile strength (TS), elastic modulus (EM) and
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energy to failure (ETF) in HERDA skin (Grady, 2009) where Types I and III fibrillar
collagen predominate in a 4:1 ratio (Lovell, 1987), lead us to hypothesize that the
HERDA phenotype extends beyond the integument to alter biomechanical properties of
diverse tissues with high fibrillar collagen content including tendon, ligament and great
vessels. Our findings indicate that the HERDA Cyclophilin B mutation results in global
alterations in fibrillar collagen molecule assembly, folding and fibril organization that
modify the mechanical properties of fibrous tissues, even when clinical signs are not
evident. This finding is of broad scientific relevance to deciphering the molecular events
that determine tensile properties of fibrous tissues. The potential relevance of these
findings to the over-representation of the HERDA allele in cutting horses with elite
performance is discussed.
We have previously demonstrated that tensile strength (TS), elastic modulus (EM)
and energy to failure (ETF) are significantly reduced in the skin of HERDA affected
horses (Grady, 2009). Skin is composed of predominantly Types I and III fibrillar
collagens in a 4:1 ratio (Epstein, 1978; Lovell, 1987). This study investigated the
hypothesis that the HERDA phenotype extends beyond the integument to alter
biomechanical properties of diverse tissues with high fibrillar collagen content including
tendon, ligament and great vessels.
Materials and Methods
Animals
Six Quarter Horses with HERDA were identified by compatible skin lesions, cosanguinity for the implicated lineage, and homozygosity for the c.115G>A missense
mutation in PPIB. Six control horses that had normal skin, and lacked the PPIB mutation
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included 4 Quarter Horses, one Quarter Horse cross and one Tennessee Walking-Horse
euthanized for conditions that did not affect the structural integrity of the tissues of
interest. HERDA genotyping was performed at Cornell University Animal Health
Diagnostic Laboratoryd. HERDA horses (4 geldings, 2 mares) were between 1.5 and 7
years old (mean 4.6). Control horses (2 geldings, 4 mares) ranged from 2-7 years of age
(mean 4.8). Investigations were approved by the University Institutional Animal Care and
Use Committee.
Tissue Collection
Full-thickness skin samples were harvested from withers, forelimb, and abdomen
using a dumbbell-shaped template as described (Grady, 2009). Great vessels were
transected 2 cm distal to the heart and 30 cm and 20 cm distal to this site in the aorta and
pulmonic artery, respectively. Forelimb superficial digital flexor tendon (SFT) and deep
digital flexor tendon (DFT) were transected proximally at the musculotendinous junction
and distally at the diaphysis of the proximal phalanx. The forelimb suspensory ligament
(SL) was transected at its origin on the palmar surface of the third metacarpal bone and
distally at each insertion with the proximal sesamoid bone. Tissues were collected within
4 hours of euthanasia, placed into evacuated whirl pakse, and stored at -80° C until
assayed.
Tissue Preparation and Thickness Determination
Tissue thickness was determined prior to tensile testing with a Mach-1™ V500cs
Micromechanical Test Systemc as described previously (Grady, 2009; Bowser, 2011).
Skin that was harvested in the requisite template shape during collection and frozen was
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equilibrated to room temperature. Tendon and ligament (SFT, DFT, SL) were thawed at
room temperature in phosphate buffered saline and cut to a dumbbell shape using a
custom template such that the tissue ends to be gripped during mechanical testing
retained their original dimensions. The body of the tissue spanning the gauge length
measured 6 mm wide. Gauge length, which is not a factor in calculations of tensile
strength, was standardized at 4 cm for tendons and ligaments based upon results from
preliminary experiments (Bowser, 2011). Tendons and ligaments with these dimensions
consistently met ASM international criteria for uniaxial tensile testing: failure in the
middle third of the gauge length and that the square root of the cross-sectional area:
gauge length did not vary between groups (variance, σ2 <0.03%), which is critical for
comparisons of elongation (Davis, 2004). Grip to grip distance for all tendinoligamentous
structures varied slightly according to height of the animal and total length of the
dissected specimen. Skin was harvested in the previously described dumbbell template
(Grady, 2009) during collection to achieve a width of 1 cm and gauge length of 6 cm was
equilibrated to room temperature. Vessels were also brought to room temperature and
were incised longitudinally to ‘unroll’ each vessel. Dumbbell shaped samples were cut
using a template so that the width and length of the section to be tested were 6.5 mm and
3 cm, respectively.
Following instrument calibration, skin and vessel thickness were determined
using a 42mm diameter circular plate lowered at 25 μm•s-1 until the sample provided 50
g of compressive resistance, reflecting an applied stress of approximately 1 KPa. For
tendons and ligaments, a cuboidal plunger was lowered at 0.1 mm•s-1, squeezing the
tissue into a rectangular cross section. Tissue dimensions were recorded when the applied
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pressure reached 0.1 MPa and specimen thickness was determined at both ends and
centrally. Thickness was recorded as the average of the three measurements.
Determination of Tensile Properties
TS, EM, and ETF were determined for skin and vessels using an Instron® 1011
Universal Testing Instrumentf as previously described (Grady, 2009). Wire mesh was
secured to the dumbbell ends of each sample using cyanoacrylic and samples were
mounted in the grips of the testing machine. Preloads of 1 newton (N) were applied to
skin samples and 0.5 N to vessels. Grip-to-grip distance and sample width were
determined with a digital micrometer. Skin was assayed using a 1000 N load beam in
conjunction with Instron® Series IX softwaref to measure displacement (mm) and force
(N) of the skin samples as they were loaded at a constant rate of 10 mm•min-1 with a
data recording rate of 10 points per second until failure. The aorta and pulmonary artery
were similarly assayed using a load beam of 50 N and sample loading at a constant rate
of 20 mm•min-1. TS of tendons and ligaments was determined using a Bionix 858 Test
Systema with 2350 L Series Controllerb and purpose-made stainless steel cryogenic
clamps as previously described (Bowser, 2011). A preload of 10 N was applied to the
mounted tissue, and grip to grip distance and sample width were measured immediately
prior to distraction at a constant rate of 0.25 mm•s-1 to failure. Force (N) and
displacement (mm) data were recorded at 100 Hz. To determine stress for all samples,
force (N) was normalized to sample cross-sectional area. TS was the maximum tensile
stress (in mega-Pascals [MPa]). For skin and vessels, sample elongation was normalized
to starting grip-to-grip length to determine strain. Strain at failure was calculated as the
percent elongation of each tissue at the point of maximal tensile stress. Skin and vessel
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EM (in MPa) were calculated as the best-fit line through the linear portion of the stress
versus strain curve. Skin and vessel ETF in millijoules per millimeter cubed (mJ/mm3)
were calculated as the area under the stress vs. strain curve to the point of failure (defined
as the point of maximum tensile stress).
Statistical Analysis
Outcome data (TS, EM, and ETF) approximated the normal distribution for all
tissues using q-q plots and the UNIVARIATE procedure in SASg software for Windows
9.2. Mixed model analysis within each tissue group for each outcome used the
GLIMMIX procedure where disease status, location, the disease status x location
interaction, sex, and age were fixed effects and horse identity was a random effect. The
threshold for significance was p<0.05. If non-significant, sex and/or age were removed
from the model. Differences in least square means were used for pairwise comparisons
among locations if location was significant and between HERDA and control skin values
at each location within a tissue group if disease status by location interaction was
significant.
Results of Study
Animals
EM was significantly higher in the skin of geldings compared to mares
(p=0.0318). Sex and age were not significantly associated with TS or ETF of skin or with
any measures in the other tissues. Tensile values and fixed effect p-values of tissues from
HERDA vs. control horses are represented in Table 2. Typical stress vs. strain curves for
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skin (withers) and vessel (aorta), and a typical stress vs. grip to grip elongation curve for
tendioligaments (SFT) of control versus HERDA animals is shown in Figure 6A-C.
Skin Samples
TS (p=0.202), EM (p=0.489), and ETF (p=0.111) were not significantly different
across skin locations (withers, abdomen, and forelimb). HERDA skin had significantly
lower TS, EM, and ETF than did control skin (p<0.001, Figure 7A-C, Table 2). The
interaction of location and disease status approached significance for TS (p=0.053) and
ETF (p=0.055) but not for EM (p=0.968). Pairwise comparisons of HERDA and control
skin at different locations revealed that although HERDA skin consistently had lower TS,
the difference was more extreme at the withers (p<0.001) than at the forelimb (p=0.034)
or abdomen (0.068). Similarly, the differences in ETF were consistently lower in
HERDA skin but were more extreme at the withers (p<0.001) than at the forelimb
(p=0.039) or abdomen (0.433). Differences in EM were similar at each of the three
locations resulting in a non-significant interaction term.
Vessel Samples
TS (p=0.018) and EM (p=0.006) were significantly lower in the aorta than
pulmonary artery while the difference in ETF, also lower in the aorta, was not statistically
significant (p=0.079) (Table 2). The EM in vessels from HERDA horses was
significantly lower (p=0.039) than in vessels from control horses. Lower TS and ETF
observed in vessels from HERDA horses relative to controls were not statistically
significant. The disease status by location interaction term was not significant for TS
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(p=0.881), EM (p=0.326), or ETF (p=0.487) indicating the significantly lower EM seen
in HERDA horses was consistent in both the aorta and pulmonary artery.
Tendinoligamentous Samples:
Location was significantly associated with TS (p<0.001). Pairwise comparisons
demonstrated that although SL had significantly lower TS than DFT (p<0.001) or SFT
(p<0.001) (Table 2), TS of DFT and SFT were not significantly different (p=0.2657). TS
was significantly lower in tendinoligamentous structures of HERDA horses compared to
control horses (p=0.016) (Figure 8). The disease status by location interaction term was
not significant for TS (p=0.577), indicating the differences seen between HERDA and
control horses were consistent across the tendinoligamentous structures that were
examined.
Discussion
More than 25 Types of collagen result from unique combinations of 3 polypeptide
chains that fold together, forming the characteristic triple-helical collagen molecule
(Miller, 1976; Fratzel, 2008). Fibrillar collagens, Types I, II, III, V, and XI, are the
structural building blocks of tissue and share similar microscopic structure in which
collagen molecules arrange in a highly ordered staggered pattern to form fibrils (Miller,
1976). Within fibrils, pyridinoline and deoxypyridinoline are intermolecular cross-links
that covalently bind the ends of the staggered collagen molecules, imparting tensile
strength (Fratzel, 2008). Relative quantities and distinctive physical characteristics of the
collagen Types in a tissue constitute a collagen fingerprint that, together with collagenmatrix interactions, shape the biomechanical properties and suitability of tissues for
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biological functions (Miller, 1976; Fratzel, 2008; Dombi, 1993). Bone collagen is almost
exclusively Type I collagen (Fratzel, 2008) and is composed of two α-1 chains and one α2 chain. In their triple helix conformation, these chains produce collagen fibrils of large
diameter that form thick fiber bundles with high resistance to deformation. By contrast,
Type III collagen is comprised of three identical α-1 chains which align compactly,
creating a smaller fibril diameter that functions as a fine mesh and imparts pliability to
tissue (Fratzel, 2008). Differences between the biomechanical properties of HERDA and
normal tissues reflect differences in tissue structural collagen that are relevant to
understanding how the PPIB mutation impacts the HERDA phenotype.
We expand on prior observation of decreased strength and increased distensibility
of HERDA skin (Grady, 2009) by demonstrating significantly weaker biomechanical
properties of great vessels and tendinoligamentous tissues from HERDA horses. Like
skin, these tissues have a predominance of Type I collagen with lesser quantities of Type
III collagen. Prior investigations of HERDA horses also identified thinning and ulceration
in HERDA corneas (Mochal, 2010), a tissue composed of a highly organized matrix of
Type I and V collagen (Fratzel, 2008), indicating that HERDA cornea possesses
clinically significant alterations in biomechanical properties. Therefore, the HERDA
phenotype includes abnormal biomechanical properties in diverse tissues with high
fibrillar collagen content, though clinical manifestations have been identified only in
integumentary tissues with very high Type I collagen content.
Consistent with Grady et al. (2009), we identify highly significant (p<0.001)
decreases in TS, ETF and EM in skin of horses with HERDA which are not restricted to
dorsal regions of the body. Unique to this report is recognition that the magnitude of
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difference in biomechanical properties between HERDA and control skin varies
significantly with the region of the skin that is tested. Differences in TS and ETF were
more extreme in skin from the dorsum (p<0.001), than forelimb (p=0.034 and 0.039) or
abdomen (p=0.068 and 0.443). The greater disparity in strength of HERDA and normal
skin along the dorsum may explain why lesions are more common on the dorsal skin of
horses with HERDA relative to skin on dependent regions (Lerner, 1978; White, 2004,
2007) which are naturally susceptible to trauma and pressure during ventral recumbence.
In addition to three regions of the skin, tensile properties of great vessels were
chosen for their similarities in collagen composition. Elastic modulus was significantly
reduced in HERDA vessels and the magnitude of this decrease was equivalent in both
aorta and pulmonary artery, indicating that HERDA vessels are more extensible than
normal vessels. Though mean TS and ETF were lower in HERDA than control horses for
both aorta and pulmonic artery, these differences did not meet the threshold of
significance. Biomechanical properties of HERDA and control vessels in this
investigation predict the ability to identify significant differences (power: 0.8, p< 0.05)
between groups in the aorta and pulmonary artery with a sample size >11 horses per
group. Disparity between collagen fiber alignment in the vascular parenchyma and the
orientation of distractive forces applied in our method was a potential confounding factor
because in vivo forces at the vascular wall primarily radiate axially, influencing collagen
alignment (Fratzel, 2008; Azadani, 2012). Axial expansion, which simulates vascular
filling, may be more appropriate to assess the tensile properties of vessels. In both
HERDA and control horses, the UTS and EM of aorta are significantly lower than
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pulmonic artery, consistent with increased extensibility that is essential for
accommodating changes in systemic blood pressure (Azadani, 2012).
Collagen constitutes 20-30% of human blood vessels (Hosoda, 1984; Barnes,
1985; Bishop, 1990), less than half of the content of skin (70%) (Lovell, 1987; Dombi,
1993), tendon (75%) or ligament (60%) (Amiel, 1984; Birch, 2008). The Type I: Type III
collagen ratio is also reduced in blood vessels (approximately 2:1) relative to other
tissues (Hosoda, 1984; Barnes, 1985; Lovell, 1987; Bishop, 1990). Type I collagen
molecules create large diameter fibrils that form thick fiber bundles with high resistance
to deformation. By contrast, Type III collagen molecules align compactly, creating a
smaller fibril diameter that functions as a fine mesh and imparts pliability to tissue
(Fratzel, 2008). Congruent with Type I collagen’s strength, tensile differences between
groups in tissues with comparatively lower total and Type I collagen should be more
subtle than tissues with comparatively higher Type I collagen content. Relative to
HERDA skin, where clinical signs are associated with a 56-80% decrease in TS (Grady,
2009), the observed TS decrease in aorta and pulmonic artery, where clinical
abnormalities have not been described, were 42 and 29%, respectively. Collectively,
these findings suggest that absence of vascular abnormalities in HERDA horses likely
reflect an insufficient magnitude of reduction in vessel strength. This could potentially be
overcome at extreme pressures. Vascular injury, including arterial rupture, is reported in
horses and certain human collagen disorders (Fratzel, 2008; Fernandes, 2008; Ploeg,
2012), but has not been documented in association with the HERDA allele.
The TS of tendinoligamentous structures was significantly reduced in HERDA
horses relative to controls (p=0.016), which was consistent across SFT, DFT and SL.
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This difference represented an 18%, 9% and 21% decrease from control values for SFT,
DFT and SL, respectively. We do not report EM and ETF for these structures because a
degree of stretch was identified at the edge of the grips where the temperature differential
was greatest, which could not be accounted for because tissue within the grips is
fundamentally expected to be rigid. Strain, as determined from grip-to-grip displacement,
could not be used to calculate EM and ETF. However, ultimate tensile strength is equal to
force per unit cross sectional area, and is independent of tissue elongation if the test
material fails uniformly in the middle third of the gauge length (Davis, 2004). All
tendinoligamentous structures failed in their midsubstance in this investigation and we
have previously substantiated that UTS of normal equine tendon assayed identically
agrees with published values from differing experimental approaches (Bowser, 2011;
Jansen 1994; Crevier, 1996).
Although EM could not be calculated for tendinoligamentous structures, multiple
investigators have documented that as UTS decreases, EM also decreases in these
structures (Thorpe, 2012, 2010; Souza, 2010). Thorpe et al (2010) specifically
demonstrated a direct positive correlation between UTS, EM and yield stress in equine
tendon that is highly significant p<0.001. Skin and vessels have a similar collagen
composition to tendinoligamentous structures, making trends in their tensile properties of
relevance. Total collagen in tendon, ligament, skin and vessel consists of 95%, 90%, 85%
and 70% Type I collagen respectively; the remainder is primarily Type III collagen
(Amiel, 1984; Birch, 2008; Lovell, 1987; Hosoda, 1984; Smith, 2005). In this study
HERDA skin had significantly reduced TS and significantly reduced EM when compared
to control skin. HERDA vessels also had significantly reduced EM and although not
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statistically significant, TS was also lower in HERDA vessels. Collectively these findings
suggest that EM would also be positively correlated to UTS in tendinoligamentous
structures in HERDA horses.
To our knowledge increased incidence of tendinoligamentous injury in HERDA
homozygotes is not reported. However, skin fragility precludes rigorous training or high
level competition with the weight of a rider, important risk factors for
tendinoligamentous injury (Minetti, 1999; Smith, 2005). Our review of the medical
records of 52 adult HERDA horses maintained on pasture at Mississippi State University
College of Veterinary Medicine from 2 months to 8 years duration within the time period
between 1996 and 2009 did not identify the occurrence of clinically evident
tendinoligamentous injuries. This agrees with reported clinical findings of a HERDA
affected foal in the first 1.5 years of life, where training on a lunge line at 14 months of
age did not reveal joint laxity or orthopedic abnormalities (White, 2007). In light of
recent evidence supporting global abnormalities in fibrillar collagen synthesis in HERDA
(Ishikawa, 2012), determining how the HERDA PPIB mutation enables decreased TS of
tendinoligamentous structures without overt clinical disease, while accounting for
decreased TS and overt disease in integumentary tissue, are clinical features that warrant
investigation.
Congruent with the HERDA phenotype that is characterized by trends in reduced
TS and EM of tissues with substantial fibrillar collagen content, Thorpe et al (2012)
recently demonstrated this same pattern in comparisons of the tensile properties of energy
storing tendons relative to positional tendons with similar Type I collagen composition.
TS and EM were significantly lower in energy storing tendons, which store potential
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energy during stretch in the stance phase of the stride and release energy during recoil in
the swing phase of the stride. This high level extension and recoil increases locomotor
efficiency by as much as 36% during high speed locomotion in the horse (Thorpe, 2012),
decreasing the energetic costs of muscular work (Minetti, 1999).
Our investigation was designed to determine if the HERDA mutation causes
global changes in tensile properties of Type I collagen rich tissues that could increase
their capacity to store potential energy. This is of interest because the HERDA allele is
segregated within the western performance discipline of cutting. The HERDA carrier
frequency is 28.3% in cutting horses, versus 3.5% in the Quarter Horse population
(Tryon, 2007, 2009). Horses that are heterozygous for the HERDA allele do not have
overt evidence of the HERDA phenotype, are over-represented among cutting horses
with elite performance, and a correlation exists between cutting lineages that carry the
HERDA allele and performance outcomes in this discipline (Tipton, 2008; equistat.com).
Cutting horses prevent a calf from rejoining a group of calves situated to the rear
of the horse. The horse mirrors the movements of the calf, necessitating successions of
rapid turns with rapid and unpredictable side-to-side accelerations and decelerations.
Locomotion of this nature has a high energetic cost. Stretch of energy storing tendons
during loading followed by recoil when unloaded can substantially increase locomotor
efficiency (Thorpe, 2012), decreasing this energetic cost of locomotion (Minetti, 1999).
This ability of a tendon to store potential energy is associated with reduced TS and EM,
reflecting the need to be more extensible (Thorpe, 2012). Interestingly, variable
heterozygote phenotypes with subtle signs of the homozygous phenotype have been
identified in investigations of PARKIN and PINK1, mutations that cause autosomal
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recessive Parkinson’s disease (Abbas, 1999; Zhang, 2000; Tan, 2003; Valente, 2004;
Khan, 2005; Hedrich, 2006; Dagda, 2009). These heterozygotes have a spectrum lacking
overt clinical disease, despite cellular evidence of dopaminergic dysfunction and subtle
extrapyramidal signs of which the patient is not aware. These collective findings:
decreased UTS of tendinoligamentous tissues, decreased EM and UTS in tissues with a
similar collagen composition to tendon and ligament, strong positive correlation between
reductions in UTS and EM that improve locomotor efficiency of tendon, and subtle
manifestations of human homozygous recessive disease phenotypes in heterozygotes
carrying the recessive allele, lead us to hypothesize that the performance advantage and
positive selection of HERDA heterozygotes in cutting may reflect altered biomechanical
properties of collagenous structures including tendons and ligaments that improve the
locomotor efficiency of HERDA heterozygotes in this discipline.
CYPB catalyzes isomerization of proline residues to the trans- configuration
during procollagen synthesis, which is required for procollagen chain association to form
the triple helical collagen molecule. This is considered the rate limiting step in collagen
synthesis (Bachinger, 1987; Pyott, 2011). However, HERDA CYPB maintains normal
prolyl-isomerization activity, substantiating that the mutation does not modify the cistrans isomerase catalytic region of CYPB, yet collagen folding and secretion are delayed
(Tryon, 2007; Ishikawa, 2012). Instead, the mutation modifies a region of CYPB that
identifies improperly folded proteins in the endoplasmic reticulum, events presumed to
alter collagen organization (Ishikawa, 2012). Decreased TS of tissues with a
predominance of Types I and III collagen identified in this investigation support this
proposed mechanism. Our findings indicate that abnormal posttranslational modification
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and disorganization of Type I and/or III collagens (and likely other fibrillar collagens)
contribute to the HERDA phenotype by modifying the biomechanical properties of
tissues rich in these collagens, even in the absence of clinical abnormalities.
Bone collagen is highly enriched for Type I collagen and both humans and mice
lacking CYPB have severe to lethal bone fragility (Van Dik, 2009; Choi, 2009; Barnes,
2010; Vranka, 2010; Pyott, 2011). By contrast, a clinically evident bone phenotype has
not been identified in association with the HERDA allele. This indicates that the HERDA
CYPB mutation modifies the biochemical basis for TS in skin while sparing or
minimizing this effect in bone as well as tendinoligamentous tissues. Based upon the
possibility of subclinical expression of heterozygote phenotypes previously discussed
(Abbas, 1999; Zhang, 2000; Tan, 2003; Khan, 2005; Hedrich, 2006; Dagda, 2009), the
potential for altered Type I collagen organization in HERDA heterozygotes provides a
rationale for investigating the role of the HERDA mutation in the increased prevalence of
osteochondrosis lesions in cutting horses (Contino, 2012) as HERDA carriers are overrepresented in elite performers (Tipton, 2008; equistat.com, Tryon, 2009).
This investigation identifies significantly lower TS of tendinoligamentous
structures and EM of great vessels from horses with HERDA, providing the first evidence
that the homozygous HERDA phenotype includes weakening of tissues that are not part
of the integumentary covering of the body. We confirmed a previously reported (Grady,
2009) significant decrease in tensile properties of skin from corporal regions that are not
on the dorsum of HERDA homozygotes and provide an explanation for the propensity to
lesions along the dorsum in HERDA because the reduced strength of HERDA skin is
more extreme at the withers relative to forelimb and abdominal skin. Accordingly, the
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homozygous HERDA phenotype is not restricted to integumentary tissues, nor to dorsal
regions of the skin, constituting a phenotype refinement that is relevant to investigating
the role of CYPB in collagen metabolism and of the CYPB mutation in clinical HERDA.
In the context of human patients that are heterozygous for PARKIN and PINK1
mutations and exhibit subtle manifestations of the associated homozygous Parkinson’s
phenotype (Abbas, 1999; Zhang, 2000; Tan, 2003; Valente, 2004; Khan, 2005; Hedrich,
2006; Dagda, 2009), the decreased TS of tendinoligamentous structures we observed in
HERDA homozygotes highlight the relevance of quantifying biomechanical properties of
tissues from HERDA carriers for attributes that could convey an advantage in disciplines
requiring extremes of flexibility and lateral movement.

39

Table 2

Tensile values (Mean, 95% Confidence Interval) and fixed effect p-values
of tissues from HERDA vs. control horses. (*significant at p<0.05)
Mean, 95% Confidence Interval

Control

HERDA

Withers

20.72, 7.30

3.97, 2.36*

Forelimb

14.24, 4.99

6.21, 2.27*

Abdomen

11.90, 7.21

5.09, 1.70

Average

15.62, 3.99

5.09, 1.36*

Tensile Strength (MPa)
Skin

Vessels
Aorta

0.45, 0.16

0.26, 0.05

Pulmonic Artery

0.76, 0.34

0.54, 0.18

Average

0.61, 0.16

0.40, 0.10

Tendinoligaments
SFT

111.32, 9.23

90.90, 15.66

DFT

111.82, 9.23

101.64, 9.94

SL

63.39, 12.15

49.89, 8.49

Average

95.51, 12.15

80.81, 12.38*

P-values for Fixed Effects in Model

Disease
Status

Location

Disease Status x
Location Interaction

<0.001*

0.202

0.053

0.092

0.018*

0.881

0.016*

<0.001*

0.577

<0.001*

0.489

0.968

0.039*

0.006*

0.326

0.001*

0.112*

0.055

0.174

0.079

0.487

Elastic Modulus (MPa)
Skin
Withers

48.89, 19.43

14.93, 4.42*

Forelimb

56.81, 26.43

23.10, 8.16*

Abdomen

48.07, 32.34

17.42, 5.43

Average

51.26, 14.54

18.48, 2.55*

Aorta

0.90, 0.35

0.55, 0.13

Pulmonic Artery

2.04, 0.87

1.18, 0.32

Average

1.47, 0.46

0.86, 0.20*

Vessels

Energy to Failure
(mJ/mm3)
Skin
Withers

4.99, 1.73

1.26, 1.07*

Forelimb

3.85, 1.66

1.90, 0.66

Abdomen

2.25, 0.98

1.54, 0.87

Average

3.70, 0.97

1.56, 0.62*

Vessels
Aorta

0.18, 0.08

0.09, 0.02

Pulmonic Artery

0.22, 0.04

0.19, 0.09

Average

0.20, 0.05

0.14, 0.04
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Figure 6

Representative Tissue Stress vs. Strain Curves.

A: skin (withers) and B: vessel (aorta), and stress vs. grip to grip elongation curve for C:
Tendinologaments (SFT) of control (▲) versus HERDA (●) horses.
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Figure 7

Tensile Properties of Control and HERDA Skin.

Data is represented as the mean (●) and 95% confidence interval (▼,▲) for TS (A),
elastic modulus (B), and energy to failure (C) of control (n=18) and HERDA (n=18) skin.
*p<0.001.
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Figure 8

Tensile Strength Control and HERDA Tendinoligaments.

Data is represented as the mean (●) and 95% confidence interval (▼, ▲) for TS of
control (n=18) and HERDA (n=18) tendinoligaments. *p=0.016.
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CHAPTER IV
LYSYL HYDROXYLASE-1 AND CYCLOPHILIN-B INTERACTIONS: PROPOSED
MECHANISM FOR ETIOPATHOGENESIS OF HEREDITARY EQUINE
REGIONAL DERMAL ASTHENIA

Summary
Objective
The objective of this investigation was to identify the molecular mechanisms by
which the HERDA mutation in the gene encoding Cyclophilin-B (PPIB) causes the
clinical syndrome of skin fragility in HERDA Quarter Horses. Based upon prior
investigations in our laboratory (Hill, 2010) that demonstrated decreased lysine
hydroxylation and an associated increase in deoxypyridinoline in HERDA skin, we
hypothesized that the HERDA PPIB mutation modifies an uncharacterized interaction
between Cyclophilin B (CYPB) and Lysyl Hydroxylase-1 (LH1). This interferes with
hydroxylysine synthesis and its availability for collagen crosslink formation. In addition,
the HERDA PPIB mutation may also lead to modifications of other known CYPB protein
complexes, such as the prolyl-3hydroxylase-1: cartilage associated protein: cyclophilin B
triplex.
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Methods
Two methods were used to identify the putative interaction between CYPB and
LH1 and to identify modification of this interaction by the HERDA CYPB mutation.
First, co-immunoprecipitation (Co-IP) was performed on liver tissue and cultured
fibroblasts from both control and HERDA affected horses. Co-IP was instituted initially
with antibody to CYPB followed by western blot analysis of the precipitate using antiLH1. This method was also reversed such that Co-IP was performed using anti-LH-1
followed by western blot analysis using anti-CYPB. In situ interaction between CYPB
and LH1 in HERDA homozygotes, heterozygotes, and horses lacking the HERDA allele
was assessed in fibroblasts using proximity ligation assay (PLA). PLA was also used to
assess interaction between prolyl-3 hydroxylase-1 (P3H1) and cartilage associated
protein (CRTAP) in control and HERDA homozygous fibroblasts.
Study Results
Interaction between CYPB and LH1 was confirmed using PLA in equine
fibroblasts. This CYPB-LH1 interaction was identified in fibroblasts from horses that
were homozygous and heterozygous for the HERDA allele, as well in control horses that
lack the HERDA allele. However, the relative quantity of the CYPB-LH1 interaction was
reduced in both HERDA homozygotes and heterozygotes when compared to controls.
Protein-protein interaction between P3H1 and CRTAP was also documented using PLA
in fibroblasts from HERDA homozygotes and controls. In this experiment the degree of
interaction was reduced in fibroblasts from HERDA homozygotes relative to controls
without the HERDA allele.
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Conclusion and Significance
These results substantiate our hypothesis that a protein-protein interaction occurs
between CYPB and LH1 during collagen processing. Counter to findings in a prior
investigation (Ishikawa, 2012), these results also indicate that the CYPB-LH1 interaction
does occur in fibroblasts containing either one or two copies of the mutant HERDA PPIB
allele but this interaction is attenuated in the presence of the HERDA CYPB mutation. In
addition, interactions between P3H1 and CRTAP were also attenuated in cells
homozygous for the PPIB mutation. In light of our prior evidence of decreased lysine
hydroxylation and altered collagen cross-linking in HERDA skin, this information refines
the mechanistic link between the HERDA PPIB mutation and the disease phenotype of
fragile hyper-extensible skin. Our prior finding (Hill, 2010) of decreased hydroxylysine
concentrations in collagen from HERDA homozygotes suggests that interactions between
CYPB and LH1 are necessary for proper post-translational hydroxylation of lysine
residues in procollagen. Decreased hydroxylysine availability as a substrate for
intermolecular collagen crosslinking would decrease collagen tensile strength and
modifying elasticity consistent with our findings in tissues with high fibrillar collagen
content (Bowser, 2012). In addition, the evidence of decreased interaction between
CYPB and LH1 in cells from HERDA heterozygotes represents a quantifiable phenotype
in animals with a single copy of the PPIB mutation. This provides a mechanistic basis
from which to investigate the link between heterozygosity for the HERDA allele and a
performance advantage in the western performance discipline of cutting (Tipton, 2008;
equistat.com).
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Introduction
Hereditary equine regional dermal asthenia (HERDA), also known as
hyperelastosis cutis (HC) is an autosomal recessive genetic disease of Quarter Horses and
related breeds that is characterized by fragile skin that is velvety in texture, loose and
hyper-extensible (Lerner, 1978; Hardy, 1988; Pascoe, 1999; Stannard, 2000; White,
2004, 2007). The proposed causal mutation, a c.115G>A missense mutation in the gene
encoding Cyclophilin B (PPIB) has to date been found to segregate in concordance with
symptomatic horses and known inbreeding loops for heterozygosity (Tryon, 2007, 2009;
Ishikawa, 2012). A member of the peptidyl-proplyl isomerase family of proteins, CYPB
executes certain essential chaperoning functions during fibrillogenesis (Kozlov, 2010;
Zhang, 2003; Smith, 1995; Horibe, 2002; Meunier, 2002). These functions include cistrans isomerization of peptidyl-prolyl bonds in procollagen chains, thus catalyzing
collagen triple helix formation (Bachinger, 1987; Liu, 1990; Smith, 1995; Kanty, 2005;
Pyott, 2011). In addition, CYPB complexed with prolyl 3-hydroxylase 1 (P3H1) and
cartilage associated-protein (CRTAP) act together to catalyze hydroxylation of proline
residues at position 986 of the α1 chains of type I, II, and III collagen (Ishikawa, 2009).
Mutations in any of these 3 proteins decreases Pro-986 hydroxylation and are among the
causes of severe to lethal recessive osteogenesis imperfecta (OI) (Van Dik, 2009; Choi,
2009; Barnes, 2010; Vranka, 2010; Pyott, 2011).
Recently, it was found that the HERDA mutated CYPB retains cis-trans
isomerization activity, but shows delayed collagen folding and secretion (Ishikawa, 2012)
without over-hydroxylation of lysine residues, a phenomenon termed over modification
that is typically associated with delayed collagen secretion (Willing, 1988; Cabral, 2007;
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Christiansen, 2010). The region on the CYPB protein altered by the HERDA mutation is
not associated with cis-trans isomerization catalysis, but with identification of improperly
folded proteins in the endoplasmic reticulum (Kozlov, 2010) and lysyl hydroxylase1(LH1) association (Ishikawa, 2012). Furthermore, analysis of Pro-986 hydroxylation in
type I collagen yielded only minor changes in HERDA versus control skin and tendons
(Ishikawa, 2012).
Clinically similar connective tissue dysplasias of both autosomal recessive and
dominant natures have been documented in a wide array of mammalian species such as
cats, dogs, cattle, sheep, rabbits, mice and man (Arlein, 1947; Minor, 1983; Holbrook,
1980; Sequeira, 1999; Tajima, 1999; van Halderen, 1988; Brown, 1993; Harvey, 1990;
Choi, 2009). Ehlers-Danlos syndromes (EDS) are a heterogenous group of inherited
connective tissue disorders in people where skin hyperextensibility and tissue fragility
closely resemble the HERDA phenotype (Lerner, 1978; Hardy, 1988; Brounts, 2001;
White, 2004). EDS VIA is an autosomal recessive disorder of LH1 activity (Yeowell,
2000; Uzawa, 2003), which is responsible for hydroxylation of lysine residues in
procollagen peptides (Valtavaara, 1997; Myllylä, 1998). EDS VIA individuals have
significantly decreased procollagen hydroxylysine residues which are essential for
formation of covalent pyridinium crosslinks in Type I collagen (Mao, 2001; Fernandes,
2008). Furthermore, the ratio between the 2 most common pyridinium crosslinks,
deoxypyridinoline (DPD): pyridinoline (PYD) is greatly increased, which is currently
used for diagnosis of this condition (Pasquali, 1994; Mao, 2001; Fernandes, 2008).
Affected HERDA horses also exhibit both reduced total hydroxylysine in skin and the
increased ratio of DPD: PYD in both skin and urine, (Swiderski, 2006; Hill, 2010) while
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having normal LH1 activity and sequence (Pasquali, Bayrak-Toydemir, unpublished).
Ishikawa recently demonstrated that recombinant equine (wild type) CYPB expressed in
E. coli binds to LH1 in rough endoplasmic reticulum (rER) extract from chick embryos,
but this binding did not occur in the presence of similarly expressed recombinant
HERDA CYPB (Ishikawa, 2012). Collectively our findings substantiate a novel
interaction between Cyclophilin B and LH1 which is modified by the HERDA PPIB
mutation.
The objective of this study was to first document the presence of binding between
CYPB and LH1 in horse fibroblast cell lines and to evaluate differences in the degree of
this CyPB-LH1 interaction within HERDA homozygous, heterozygous and control
animals. In addition, we sought to also measure the degree of interaction between P3H1
and CRTAP in HERDA homozygous and control horses.
Materials and Methods
Samples
Sample collection and use in this investigation was approved by the Institutional
Animal Care and Use Committee (IACUC). Disease status of all samples was confirmed
via HERDA genotyping by Dr. Nena Winand, Cornell University Diagnostic Laboratoryd
or the Veterinary Genetics Laboratory, University of California, Davish.
Liver Tissue Collection
Liver tissues were harvested from control and HERDA homozygous horses
following humane euthanasia at the Mississippi State University College of Veterinary

49

Medicine. Samples were collected within 2 hours of euthanasia, placed into evacuated
whirl paks (Nascoe, Cat# B00679WA), and stored at -80°C until assayed.
Fibroblast Cultures
Skin fibroblast cultures from control and HERDA homozygous horses were
prepared from dermal punch biopsies collected antemortem using aseptic conditions or
from skin collected immediately post mortem. The skin was minced in Dulbecco’s
phosphate buffered saline (DPBS) containing 200 μg/ml penicillin/streptomycin (SigmaAldrichi, Cat# P433). Minced tissue fragments were resuspended in fibroblast media
(Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham media (SigmaAldrichi, Cat# D6421) containing 20% fetal bovine serum (FBS) (Gemini Bio-Productsj,
Cat# 100-106), 100 μg/ml penicillin/streptomycin (Sigma-Aldrichi, Cat# P433) and 2mM
L-glutamine (Sigma-Aldrichi, Cat# G7513), and plated in 6 well plates that were
precoated with fibronectin coating mix (Athena Enzyme Systemsk, Cat# 0407). Cells
were incubated at 37oC in atmosphere supplemented to 5% CO2, monitored for outgrowth
and passaged serially from 25cm2 to 50cm2 flasks. At 70% confluence, cells were rinsed
3 times in DPBS, detached from flasks via trypsinization and centrifuged at 1000 rpm for
10 minutes. Cells were counted and 2- 2.5 x 106 cell aliquots were resuspended in media
with 20% FBS. DMSO (Sigma-Aldrichi, Cat# 472301) was added dropwise to achieve a
10% solution. Aliquots were then placed in an isopropyl alcohol cell freezer designed to
assure proper freezing of eukaryotic cells to -80oC at 1oC per minute (Mr Frosty,
Thermo Scientificl, Cat# 5100-0001), placed at -80°C overnight, and transferred to
cryopreservervation (-256°C).
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For experiments evaluating collagen metabolism, cells were defrosted at room
temperature, and cultured in 25cm2 flasks in fibroblast media at 37°C in 5% CO2. At 90%
confluence cells were transferred to single well (~110 cm2) plates (Thermo Scientific l,
Cat# 165218). Growth was monitored until ~80 % confluence and then 50μg/ml ascorbic
acid (Sigma-Aldrichi, Cat# A4403) was added to the media 18 hrs prior to harvesting. At
collection, cells were washed three times with DPBS and scraped into 1.5ml
microcentrifuge tubes, pulse centrifuged to produce a cell pellet, and supernatant
discarded. Cell pellets (approximately ~108cells) were stored @ -20°C until assayed.
Fibroblast Lysate Preparation
Immediately prior to assay, one, two, four or eight previously collected cell
pellets from each cell line were thawed, and lysed in NP40 Cell Lysis Buffer
(Invitrogenm, Cat #FNN0021) containing protease inhibitor (Sigma-Aldrichi, Cat# P2714)
via 30 minute incubation on ice with vortexing every 10 minutes. Samples were
centrifuged at 10,000rpm x 10min at 4° C and the pellet discarded.
Endoplasmic Reticulum Enriched and Purified Lysate Preparation
Endoplasmic reticulum enriched and purified post mitochondrial fraction (ERPMF) lysates were obtained from both cultured fibroblasts and liver tissue using the ER
Isolation Kit (Sigma-Aldrichi, Cat# ER0100-1KT).
Fibroblast ER-PMF
Fibroblast cell pellets (~108 cells/pellet) previously described were thawed, resuspended in a volume of 1X Hypotonic Extraction Buffer (Sigma-Aldrichi) equivalent to
3 times the cell pellet packed cell volume (PCV) and incubated for 20 minutes at 4°C.
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Subsequently, the cells were centrifuged at 600 x g for 5 minutes and the supernatant was
removed by aspiration. PCV was again measured and a volume of 1X Isotonic Extraction
Buffer (Sigma-Aldrichi) equivalent to 2 times the new PCV was added. The mixture was
sheared through a 23 gauge needle with a 5 mL syringe 3-5 times to produce a
homogenate.
The homogenate was maintained on ice and centrifuged at 1000 x g for 10
minutes at 4°C. The thin floating lipid layer was carefully aspirated and the post nuclear
supernatant was pipetted into a clean microfuge tube and pellet discarded. The
supernatant was centrifuged at 12000 x g for 15 minutes at 4°C and lipid layer carefully
removed by aspiration again. The clear post nuclear supernatant ER-PMF was transferred
into another clean microcentrifuge tube and pellet discarded. Proteins in the post nuclear
supernatant ER-PMF were precipitated by adding 7.5 volumes of 8mM Calcium Chloride
Solution (Sigma-Aldrichi) dropwise with constant stirring. The solution was stirred for an
additional 15 minutes at 4°C and centrifuged at 8000 x g for 10 minutes. The pellet was
resuspended in 0.3 mL of 1X Isotonic Extraction Buffer (Sigma-Aldrichi) for subsequent
use in the co-immunoprecipitation assay described below.
Liver ER-PMF
Liver tissue samples (1 g per assay) were sliced into 2mm pieces, rinsed twice in
DPBS, blotted to remove excess blood contamination and pulverized by passage through
a stainless steel wire mesh with glass homogenizer and 1X Isotonic Extraction Buffer
(3.5mL/g tissue). The homogenate was then processed identically to the fibroblast
homogenate described previously to produce a hepatocyte ER-PMF.
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Co-Immunoprecipitation
Protein content of the ER fractions (fibroblast and hepatocyte ER-PMF) were
estimated by diode array spectrophotometer (NanoDrop 2000, Thermo Scientific l) and
protein quantity standardized between samples before proceeding to Coimmunoprecipitation (Co-IP). A protein G magnetic bead kit (Dynabeads, Invitrogenm,
Cat# 100.07D) was used in all Co-IP reactions according to product instructions. Protein
G coated magnetic beads were prepared by 60 minute incubation with 2 μg primary
antibody in 200μl antibody binding and washing buffer (Invitrogenm). Primary antibodies
were either rabbit origin polyclonal anti-CYPB (Abcamq, Cat# ab16045) for the forward
assay (Co-IP using anti-CYPB with detection of LH1 by western blot), or goat origin
polyclonal anti-LH1 (Santa Cruz Biotechnologyn, Cat# sc-50063) for the reciprocal assay
(Co-IP using anti-LH1 with detection of CYPB by western blot). To minimize antibody
dissociation from the beads, primary antibody was crosslinked to the magnetic beads
using bis[sulfosuccinimidyl] suberate (BS3, Thermo Scientificl, Cat# 21586) at a 10 fold
molar excess to the primary antibody. Following incubation at room temperature for 30
minutes, the crosslinking reaction was quenched using Tris at a final concentration of
40mM for 15 minutes. Protein G coated magnetic beads with crosslinked anti-CYPB
were washed three times with 200μl phosphate buffered saline with Tween 20 (PBST)
and separated from the supernatant using a magnet.
Anti-CYPB coated magnetic beads were incubated with the prepared cell lysates
for 60 minutes at room temperature with rotation and gentle pipetting. Beads were
separated from the supernatant with a magnet, washed 3 times using 200μl washing
buffer (Invitrogenm) per sample, resuspended in 100μl washing buffer and transferred to
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1.5ml microcentrifuge tubes. Proteins were eluted from the magnetic beads by adding
40μl elution buffer (Invitrogenm), 20μl NuPAGE LDS Sample Buffer (Invitrogenm) and
incubating at 95°C for 10 minutes.
Polyacrylamide Gel Electrophoresis
Following elution and heating, samples from Co-IP were immediately quenched
on ice and pulse centrifuged prior to loading onto precast polyacrylamide gels (Criterion
TGX-Any kD, Bio-Rado, Cat# 567-1123). Gels were run in duplicate by loading half of
the eluted Co-IP product (by volume) to produce 2 identical gels. Control lanes on each
gel included recombinant Human CYPB protein (ProSpec-Tany TechnoGenep, Cat#
ENZ-313), rabbit origin polyclonal anti-CYPB Antibody (Abcamq, Cat# ab16045),
mouse ovarian extract as an LH1 control (Santa Cruz Biotechnologyn, Cat#.sc-2404). A
protein molecular weight standard was incorporated in the outer flanking wells (Magic
Mark, Invitrogenm, Cat# LC5603). Proteins were resolved by electrophoresis at 4°C
overnight in 1X NuPAGE MES SDS running buffer (Invitrogenm, Cat# NP0002).
Early in the protocol, one of the duplicate gels was stained with silver stain
(Piercer, Cat# 24600). Later, due to concerns about silver interference with mass
spectrometry analysis, the duplicate gel was stained with GelCode Blue (Thermo
Scientificl, Cat# 24590). Silver staining was conducted per kit protocol directions.
GelCode Blue stain, a modified coomasie dye with increased protein detection sensitivity
above traditional coumassie blue staining (sensitivity approaching 8 nanograms), was
used per kit protocol instructions.
LH1 is a homodimer. Consistent with ER fraction proteins, the predicted
sequence for equine LH1 (NCBI-GI: 149695386) in the absence of post-translational
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modification would migrate in the range of 84 kD. Human LH1 is estimated to migrate at
85kD (Valtavaara, 1997). Human CYPB monomer has a predicted molecular mass of
21kD (Endrich, 1999) and equine CYPB (NCBI- GI:153792483), in the absence of posttranslational modification has a predicted molecular mass of 23.563 kD. Following
staining, bands visible in these regions were cut from the gel and frozen at -80°C for later
analysis.
Western Blot Analysis
Following gel electrophoresis of immunoprecipitated proteins, one of the
duplicate polyacrylamide gels was immediately transferred to polyvinylidene difluoride
(PVDF) membrane (Bio-Rado, Cat# 162-0236) by electrophoresis at 60 volts for 90 min.
The membrane containing transferred protein was subjected to modified western blot
(Sambrook, 2001). Briefly, the membrane was blocked overnight at 4°C with 5% bovine
casein (Bio-Rado, Cat# 170-6404), incubated one hour with either goat origin anti-LH1
(Santa Cruz Biotechnologyn, Cat# sc-50063) or rabbit origin anti-CYPB (Abcamq, Cat#
ab16045) and washed four times for 5 minutes with Tris-Tween Buffered Saline (TTBS).
The membrane was then incubated 1 hour with either donkey anti-goat IgG-HRP (Santa
Cruz Biotechnologyn, Cat# sc-2020) for to detect LH1, or goat anti-rabbit IgG-HRP
(Santa Cruz Biotechnologyn, Cat# sc-2004) to detect CYPB. The membrane was washed
4 times (5 minutes per wash with TTBS), incubated for 5 minutes with horseradish
peroxidase enhanced chemiluminescence solution (Piercer, Cat# 34087) and imaged on a
Bio-Rad ChemiDoc XRS+ System (Bio-Rado).
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Proximity Ligation Assay
Fibroblast Preparation
Skin fibroblast cultures from control, HERDA heterozygous and homozygous
horses were prepared from skin biopsies as previously described. Cells were plated into
12-well plates containing 10mm diameter glass coverslips and grown in AmnioMAX
media (Invitrogenm, Cat# 11269-016) containing Alpha-MEM Earle’s Salts (Irvine
Scientifics, Cat# 9144), 20% fetal bovine serum (Gemini Bio-Productsj, Cat# 100-106),
100 μg/ml penicillin/streptomycin (Sigma-Aldrichi, Cat# P433) and 2mM L-glutamine
(Sigma-Aldrichi,Cat# G7513) and allowed to attach overnight. Cells were incubated in
the presence of ascorbic acid (50μg/ml) (Sigma-Aldrichi, Cat# A4403) for 18 hours prior
to use in the immunofluorescence or proximity ligation assays.
Immunofluorescence
Immunofluorescence was performed using a modified protocol from Abcam.
Briefly, fibroblast cells as described previously were rinsed with cold 1× phosphate
buffered saline (PBS), fixed with 4% paraformaldehyde in 1× Sorenson’s solution
(Abcamq) for 15 minutes at room temperature and permeabilized with 0.25% Triton X100 in 1× PBS at room temperature for 12 minutes. Following a 1 hour blocking
treatment in either 2% goat serum (Zymedt, Cat# 10000C) for cells to be incubated with
anti-CRTAP, anti-P3H1, or anti-CYPB; or Duolink block solution (Olinku) for cells to be
incubated with anti-LH1 at room temperature, primary antibodies to CYPB (Abcamq,
Cat# ab16045), LH1 (Santa Cruz Biotechnologyn, Cat# sc-50063), CRTAP (Morello v) or
P3H1 (Abnovaw, Cat# H00064175-B01P) were added in separate wells and allowed to
hybridize at room temperature for two hours. Secondary antibodies conjugated to
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fluorophores (Jackson Laboratoriesx, Cat# 111-075-144, 705-095-147): goat anti-rabbit
TRED (1:400), donkey anti-goat FITC (1:200); (Molecular Probesy, Cat# A11008,
A11032): goat anti-rabbit Alexa Fluor 488 (1:800), goat anti-mouse Alexa Fluor 594
(1:800) were then incubated with cells as appropriate for the primary antibody at room
temperature for one hour. Coverslips were mounted on glass slides with 4′, 6-diamidino2-phenylindole (DAPI) (Prolong +, Invitrogenm, Cat# P36935). Cells were visualized
microscopically using fluorescence detection (Nikon microphot-SA microscope, Nikon
Instrumentsz) and digitally imaged(Photometrics sensys, Photometricsaa).
Proximity Ligation
The Duolink in situ Proximity Ligation Assay (PLA, Olink Bioscience u) was used
to detect interactions between CYPB and LH1, and also between CRTAP and P3H1. The
Duolink system employs oligonucleotide-labeled secondary antibodies (PLUS and
MINUS probes with complementary DNA sequences) to each of the primary antibodies
(CYPB and LH1 or CRTAP and P3H1) that, in combination with a DNA amplificationbased reporter system, generate a fluorescent signal only when the two primary
antibodies are in close proximity (Wilhelm, 2010). Signal from a single pair of primary
antibodies is visualized as a fluorescent spot (see Figure 9 for an overview of the PLA
method).
Briefly, fibroblasts were cultured in vitro, fixed, permeabilized and blocked with
Duolink block solution as previously described for immunofluorescence. PLA was
performed as per manufacturer’s instructions. Antibodies for both CYPB (1:100) and
LH1 (1:100), or both CRTAP (1:2000) and P3H1 (1:4000) were added to each well and
incubated for 1hour 40 minutes. Coverslips were washed with 1× PBS and incubated
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with PLA probe solution (Olinku) containing PLUS and MINUS probes in a humidity
chamber at 37° C for one hour, washed again, and incubated with Duolink Ligase-Ligase
solution (Olinku) for 30 minutes in the same conditions as the previous step. Coverslips
were washed using Duolink 1X Wash Buffer A (Olinku) and incubated with polymerase
containing amplification solution (Olinku) in a humidity chamber at 37° C for 1 hour 40
minutes. Finally, the cells were washed using Duolink Wash Buffer B (Olink u) in
decreasing concentration (1X, then 0.01X), coverslips were allowed to dry and mounted
in Duolink II Mounting Media (Olinku) with DAPI (Invitrogenm, Cat# P36935). Images
were captured as described previously.
Results of Study
Co-Immunoprecipitation
Silver stained gels produced by forward (anti-CYPB) immunoprecipitation of
fibroblast lysate from 1, 2, 4 or 8 cell pellets produced no or equivocal discernible bands
at ~85kD where LH1 migration is anticipated. Silver stained gels produced by reciprocal
(anti-LH1) immunoprecipitation of increasing fibroblast lysate concentrations also failed
to demonstrate appropriate 21kD bands congruent with CYPB pull-down. Use of
increasing numbers of cells enhanced non-specific binding during the Co-IP procedure
and increased background signal in the western blot analysis. Neither LH1 nor CYPB
were identified by western blot analysis from Co-IP of non-ER enriched fibroblast
lysates.
Silver stained gels produced by forward (anti-CYPB) immunoprecipitation of ER
enriched fibroblast lysate demonstrated faint bands of ~85kD suggestive of LH1 pull-
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down. However, western blot of this anti-CYPB derived Co-IP product to identify LH1
was negative or equivocal.
Silver stained gels produced by anti-CYPB initiated immunoprecipitation of ER
enriched and purified hepatocyte lysate produced moderate bands of correct ~85kD
weight appropriate for LH1 pull-down (Figure 10). Furthermore, western blot analysis of
these assays produced some positive LH1 signal (Figure 11). Unfortunately, mass
spectrometry of these fragments failed to confirm them as LH1. Following this,
subsequent gels produced from immunoprecipitation of ER enriched and purified
hepatocyte lysate were stained using a coomassie blue (GelCode Blue, Pierce r) based
staining method in order to minimize interference with mass spectrometry analysis.
Appropriate bands visualized using this staining technique were fainter, but still visible.
Again mass spectrometry analysis failed to confirm the bands as LH1.
Proximity Ligation
Immunofluorescence assays using control fibroblasts confirmed good intracellular
staining by the CYPB, LH1, CRTAP and P3H1 primary antibodies (Figure 12) for use in
subsequent PLA procedures. Furthermore, these proteins appeared to concentrate in a
peri-nuclear pattern appropriate for residing in the endoplasmic reticulum.
CYPB-LH1 Interaction
Positive interaction between CYPB and LH1 was found via PLA in equine
fibroblasts homozygous, heterozygous and lacking the HERDA PPIB mutation (Figure
13). Total relative quantity of individual CYPB-LH1 complexes (fluorescent spots) was
reduced in HERDA homozygotes and heterozygotes when compared to controls. The
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total quantity of individual CYPB-LH1 complexes in both heterozygote and homozygote
fibroblasts appeared to be roughly 50% reduced from control fibroblasts lacking the
HERDA allele. Quantitative analysis of differences in protein-protein interactions
necessitates analysis with proprietary software.
CRTAP-P3H1 Interaction
Positive interaction between P3H1 and CRTAP was found using PLA in equine
fibroblasts homozygous for the HERDA PPIB mutation and lacking the mutation (Figure
14). Relative to the quantity of CRTAP-P3H1 interactions detected in control fibroblasts,
CRTAP-P3H1 interactions were reduced in HERDA homozygote cells. The total quantity
of individual CRTAP-P3H1 interactions in HERDA homozygous fibroblasts was roughly
70% reduced from control fibroblasts without the HERDA allel. Quantitative analysis of
differences in CRTAP-P3H1 complex formation associated with the HERDA mutation
necessitates software analysis.
Discussion
Procollagen chain modification, assembly and secretion from the endoplasmic
reticulum is a complex and incompletely understood biological process that necessitates
the coordinated interaction of many proteins (Gunson, 1979; Liu, 1990; Zhang, 2003;
Canty, 2005; Krane, 2008; Fratzel, 2008). Recent advances in our understanding of the
intricacies of these interactions (Choi, 2009; van Dik, 2009; Barnes, 2010; Ishikawa,
2009, 2011; Pyott, 2011) have led to a new depth of insight into the multiple orchestrated
protein-protein interactions needed to catalyze these events. A member of the peptidylproplyl isomerase family of proteins, CYPB is known to 1) trans isomerize (Xaa-Pro)
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peptide bonds from the cis- configuration (Bachinger, 1987; Liu, 1990; Smith, 1995;
Kanty, 2005; Pyott, 2011), 2) chaperone HSP47 for proper stabilization of the collagen
triple-helix within the rER(Smith, 1995) and 3) create a triplex along with P3H1and
CRTAP for 3-hydroxylation of Pro986 on α1(I) and Pro707 on α2(I) chains (Ishikawa,
2009). As a member of the family of 2-oxoglutarate dioxygenases, LH1 catalyzes the
hydroxylation of lysine residues in X-Lys-Gly triplets (Valtavaara, 1997; Myllylä, 1998).
In this study we have successfully documented by PLA that CYPB and LH1, previously
known to act separately, in fact act in close association with each other within the
endoplasmic reticulum of fibroblasts.
Duolink PLA is a highly sensitive, highly specific in-situ method for detection
and visualization of interactions at the single molecule-molecule level (Wilhelm, 2010).
This procedure is often sensitive enough to detect weak associations that cannot
withstand more rigorous purification methods and can identify protein associations within
the more natural environment of a cell, preserving the un-denatured conformation of the
protein and better reflecting in-vivo molecular relationships. In contrast, coimmunoprecipitation produces best results from strong, robust and numerously occurring
protein-protein interactions. We suspect that the action of CYPB in association with LH1
is of a chaperoning nature, similar to previously documented CYPB functions (Smith,
1995; Ishikawa, 2009), making the association between these two molecules transient and
reversible. Failure to substantiate CYPB-LH1 interaction by the use of coimmunoprecipitation methods in our study is likely due to limited frequency and strength
of the CYPB-LH1 interaction that occur under natural circumstances within the rER.
Recently, a CYPB-LH1 interaction by modified immunoprecipitation technique was
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successful documented using E. coli recombinant sepharose bead-bound equine CYPB
incubated with rER extract from chick embryos (Ishikawa, 2012). It is possible that this
technique helped to optimize both the amount of bead-bound CYPB and the quantity of
LH1 available for CYPB binding to produce positive western blot pull-down results that
were not apparent in the current study using more natural biologic concentrations found
within fibroblast or hepatocyte lysates. Furthermore, in Ishikawa et al. (2012),
recombinant HERDA mutated CYPB failed to bind LH1. This is in contrast to results in
the current study documenting attenuated, but still present CYPB-LH1 binding in-situ
within fibroblasts heterozygous and homozygous for the HERDA PPIB mutation. The
increased sensitivity of Duolink PLA protein-protein detection is a plausible explanation
for our ability to detect reduced, but present CYPB-LH1 binding within the present study.
The attenuation of CYPB-LH1 interactions within HERDA individuals found in
this study helps to explain why these animals have reduced lysyl hydroxylation (Hill,
2010) despite normal LH1activity and sequencing (Pasquali, Bayrak-Toydemir,
unpublished). In fact, delayed collagen folding and secretion in other diseases leads to
procollagen over modification (Willing, 1988; Cabral, 2007; Christiansen, 2010) and
increases total lysyl hydroxylation (Pasquali, 1997; Yeowell, 2000; Walker, 2004). Lysyl
hydroxylation is reduced in HERDA individuals despite the presence of delayed collagen
folding, a phenomenon that could not be explained prior to documentation of CYPB-LH1
interaction. The mutant HERDA CYPB attenuates CYPB-LH1 interaction, a step we
hypothesize to be essential for optimal lysyl hydroxylation of lysine to hydroxylysine
residues on the triple helical region of procollagen chains. This reduction in total
hydroxylysine residues (Hill, 2010) leads to the preferential formation of the covalent
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pyridinium crosslink, deoxypyridinoline (DPD), which is derived from less
hydroxylysine residues (two hydroxylysines and one lysine) compared to pyridinoline
(PYD), formally derived from 3 hydroxylysine residues. In the presence of unaltered
CYPB, PYD is the most prevalent of the crosslinks, reflecting normal hydroxylation of
both telopeptide and triple helical regions of collagen. The preferential formation of DPD
observed in HERDA results in reversal of the DPD:PYD ratio in these horses (Hill,
2010), a phenomenon that is also documented in human patients with EDS VIA and
impaired LH1 function (Beighton, 1997; Mao, 2001; Fernandes, 2008).
The finding that interaction between CRTAP and P3H1 is attenuated in HERDA
homozygous fibroblasts is unexpected and interesting. CYPB participates in a collagenmodifying complex with CRTAP and P3H1, which together hydroxylate the proline at
position 986 (P986) in the α1 chains of type I and type II collagens (Ishikawa, 2009). It is
not surprising that the HERDA CYPB mutation alters optimal interaction between
CRTAP and P3H1 in situ. Interestingly, mutations of any of these 3 components inhibits
or impedes P986 hydroxylation and causes severe or lethal autosomal recessive
osteogenesis imperfecta (OI) (Marini, 2007; Cabral, 2007; Choi, 2009; Vranka, 2010). OI
is a disorder characterized by osteoporosis, bone fragility, and fractures that may be
accompanied by bone deformity, tooth malformations, short stature, and shortened life
span (King, 1971). Bone fragility has not been demonstrated in HERDA affected horses.
Furthermore, analysis of Pro-986 hydroxylation in type I collagen yielded only minor
changes in HERDA versus control skin and tendons (Ishikawa, 2012). Further
investigation into the effect of attenuated CRTAP: P3H1 interaction of HERDA
homozygotes on bone formation is warranted.
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This study, to our knowledge, is the first documentation of altered protein-protein
interaction in animals heterozygous for the HERDA allele. Previously, alterations in the
tensile properties of connective tissues of HERDA affected animals have led us to
hypothesize that carrier animals might also have altered (to a less extent) tensile
properties of these structures (Bowser, 2012) which may provide an athletic advantage in
competition. Attenuation of the CYPB: LH1 interaction in fibroblasts from HERDA
heterozygotes provides evidence to advance the hypothesis that modified CYPB-LH1
interaction in HERDA carriers alters tissue biomechanical properties and accounts for the
observed athletic advantage.
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Figure 9

Overview of the Duolink Proximity Ligation Assay.

A) Two proteins interacting in-situ. B) Target specific primary antibodies of two different
species. C) Oligonucleotide-labeled secondary antibodies (PLUS and MINUS probes). D)
Oligos connector hybridization and ligation. E and F) Rolling circle amplification. G)
Hybridization of detection probes. H) Visualization of each protein-protein complex as a
single fluorescent spot.
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Figure 10

Anti-Cyclophilin B Co-immunoprecipitates from Endoplasmic ReticulumEnriched Hepatocyte Lysates: Silver Stained Polyacrylamide Gel.

L: Protein standards. Values in kilodaltons (kD).
A1: HERDA homozygote 1, Anti-CYPB immunoprecipitate.
A2: HERDA homozygote 2, Anti-CYPB immunoprecipitate.
C1: Control 1, Anti-CYPB immunoprecipitate.
C2: Control 2, Anti-CYPB immunoprecipitate.
O: Mouse Ovarian Cell Lysate (LH1 positive control).
Pr: CYPB purified protein (CYPB positive control).
Ab: Anti-CYPB antibody.
Faint bands are visible (□) at approximately 85kD molecular weight.
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Figure 11

Western Blot Analysis of Anti-Cyclophilin B Co-immunoprecipitates from
Endoplasmic Reticulum-Enriched Hepatocyte Lysates.

L: Protein standards. Values in kilodaltons (kD).
A1: HERDA homozygote 1, Anti-CYPB immunoprecipitate.
A2: HERDA homozygote 2, Anti-CYPB immunoprecipitate.
C1: Control 1, Anti-CYPB immunoprecipitate.
C2: Control 2, Anti-CYPB immunoprecipitate.
O: Mouse Ovarian Cell Lysate (LH1 positive control).
Pr: CYPB purified protein (CYPB positive control).
Ab: Anti-CYPB antibody.
Note (○) 85 kD bands in HERDA affected and control lanes.
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Figure 12

Immunofluorescence Assays using Control Fibroblasts.

A: Secondary antibody only, donkey anti-goat FITC (1:200).
B: Secondary antibody only, goat anti-rabbit TRED (1:400).
C: Standard immunofluorescence, primary anti-CYPB antibody (1:200).
D: Standard immunofluorescence, primary anti-LH1 antibody (1:200).
E: Standard immunofluorescence, primary anti-P3H1 antibody (1:600).
F: Standard immunofluorescence, primary anti-CRTAP antibody (1:200).
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Duolink Proximity Ligation Assay (PLA) for CYPB and LH1 in Equine Fibroblasts.

A) HERDA negative, anti-CYPB only (1:100) B) HERDA negative, anti-LH1 only (1:100). C) HERDA negative, CYPB-LH1 PLA.
D) Heterozygote, anti-CYPB only (1:100). E) Heterozygote, anti-LH1 only (1:100). F) Heterozygote, CYPB-LH1 PLA.
G) Homozygote, anti-CYPB only (1:100). H) Homozygote, anti-LH1 only (1:100). I) Homozygote, CYPB-LH1 PLA.
NOTE: Single-antibody stains should not produce signal. Signal should only be present in cells stained with two antibodies.

Figure 13
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Figure 14

Duolink Proximity Ligation Assay (PLA) for CRTAP and P3H1 in Equine
Fibroblasts.

A) HERDA negative, anti-CRTAP only (1:2000) B) HERDA negative, anti-P3H1 only
(1:4000). C) HERDA negative, CRTAP-P3H1 PLA. D) Homozygote, anti-CRTAP only
(1:2000). E) Homozygote, anti-P3H1 only (1:4000). F) Homozygote, CRTAP-P3H1
PLA.
NOTE: Single-antibody stains should not produce signal. Signal should only be present
in cells stained with two antibodies.
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CHAPTER V
CONCLUSION

In this project, we have designed and validated a low cost device for quantifying
physical properties of connective tissue specimens with inherently high tensile strength.
Results of testing performed on normal equine deep digital flexor tendon indicate that
this device provides a practical method of adequately securing larger tendons and
ligaments for tensile strength testing.
Using this method, we found that HERDA horses have significantly altered
tensile properties of multiple tissues with high Type I fibrillar collagen content,
substantiating that the molecular mutation associated with HERDA that alters collagen
fibrillogenesis is not limited to the integument. In addition, these changes of reduced
tensile strength and elastic modulus of energy-storing tissues have a strong positive
correlation with improved locomotor efficiency of tendons and ligaments (Minetti, 1999;
Souza, 2010; Thorpe, 2010, 2012).
Finally, we have provided substantiation that CYPB and LH1 interact within the
endoplasmic reticulum of all fibroblasts. Furthermore, we found attenuation of this
interaction in fibroblasts containing either one or both copies of the mutant HERDA
PPIB allele and interactions between P3H1 and CRTAP also appear to be attenuated in
cells homozygous for the HERDA mutation. This information helps to further clarify the
71

mechanistic link between the known HERDA PPIB mutation and the documented disease
phenotype.
This discovery of evidence for a small but quantifiable HERDA phenotype in
heterozygotes, along with documented changes in tensile properties of
tendinoligamentous structures of homozygotes introduces the concept of heterozygote
phenotypes in animal disease and provides a plausible hypothesis for causality between
carrier status and athletic advantage.
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